Please use this identifier to cite or link to this item:
Title: Acquisition of functional antibodies that block the binding of erythrocyte-binding antigen 175 and protection against plasmodium falciparum malaria in children
Austin Authors: Irani, Vashti;Ramsland, Paul A ;Guy, Andrew J;Siba, Peter M;Mueller, Ivo;Richards, Jack S;Beeson, James G
Affiliation: Austin Health, Heidelberg, Victoria, Australia
Centre for Biomedical Research, Burnet Institute, Melbourne, Victoria, Australia
Department of Medicine, University of Melbourne, Parkville, Victoria, Australia
Department of Immunology, Monash University, Melbourne, Victoria, Australia
Department of Surgery, Austin Health, University of Melbourne, Heidelberg, Victoria, Australia
School of Biomedical Sciences, Curtin Health Innovation Research Institute-Biosciences, Curtin University, Perth, Western Australia, Australia
Papua New Guinea Institute of Medical Research, Goroka, Papua New Guinea
Infection and Immunity Division, Walter and Eliza Hall Institute of Medical Research, Parkville, Victoria, Australia
Barcelona Centre for International Health Research, Barcelona, Spain
Department of Microbiology, Monash University, Clayton, Victoria, Australia
Issue Date: 15-Oct-2015 2015-07-01
Publication information: Clinical Infectious Diseases 2016; 61(8): 1244-1252
Abstract: BACKGROUND: The targets and mechanisms of human immunity to malaria are poorly understood, which poses a major barrier to malaria vaccine development. Antibodies play a key role in human immunity and may act by inhibiting receptor-binding functions of key merozoite invasion ligands. Antibodies to the major invasion ligand and vaccine candidate, erythrocyte-binding antigen 175 (EBA-175), have been linked with protection, but how these antibodies function has not been established. METHODS: We developed 2 new assays that quantify the ability of antibodies to inhibit binding of EBA-175 to its erythrocyte receptor, glycophorin A, using either native or recombinant EBA-175. Binding-inhibitory antibodies were evaluated in a longitudinal cohort study of Papua New Guinean children and related to risk of malaria, age, infection status, and markers of parasite exposure. RESULTS: Binding-inhibition assays (BIAs) were reproducible, and the 2 assays had a high level of agreement. Inhibitory antibodies were common among children, acquired in association with markers of increasing parasite exposure, and high in those children with active infection. Inhibitory antibodies correlated with total immunoglobulin G levels to the EBA-175 binding domain (region II). Importantly, binding-inhibitory antibodies were significantly associated with protection from symptomatic malaria when measured using either BIA. CONCLUSIONS: Findings suggest that naturally acquired binding-inhibitory antibodies are an important functional mechanism that contributes to protection against malaria and further supports the potential of EBA-175 as a vaccine candidate. Identifying vaccines and approaches that induce potent binding-inhibitory antibodies may be a valuable strategy in the development of highly efficacious malaria vaccines.
DOI: 10.1093/cid/civ525
Journal: Clinical Infectious Diseases
PubMed URL:
Type: Journal Article
Subjects: EBA-175
Plasmodium falciparum
Binding inhibition
Appears in Collections:Journal articles

Show full item record

Google ScholarTM


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.